Arm's Own AI CPU Debut Fails to Halt 33% Share Decline, Wait Rating Intact

What happened

Arm has begun selling its own host CPU for AI accelerators, directly addressing the need for a CPU in every AI rack, yet shares have shed a third in the past month, reflecting a market demanding proof over potential. The DeepValue report had already flagged that Arm's premium valuation left no margin of safety at $286.70, with the stock trading at 295x earnings and 215x EV/EBITDA, and the new article does not provide new financial data to change that assessment. The sell-off aligns with earlier stress signals, including sharp drops after above-estimate outlooks and concerns about smartphone weakness and AGI CPU supply constraints. Management's disclosed line of sight to over $2 billion of AGI CPU demand across FY2027-FY2028 remains capped at a $1 billion outlook due to supply-chain capacity, and first revenue is not expected until FQ4 FY2027, leaving a long execution runway. The next key catalysts are FQ3 and FQ4 FY2027 reports, where royalty growth near 20% and AGI CPU revenue visibility will determine whether the stock's AI narrative can finally be backed by filing-level proof.

Implication

The stock's valuation leaves little room for error, and the recent decline reflects market skepticism about execution rather than any fundamental break in Arm's architecture moat. Over the next six months, the critical test is whether management can raise the AGI CPU outlook above $1 billion and confirm that first revenue will land in FQ4 FY2027 without further supply-chain slippage, as any delay would undermine the production-silicon thesis. Simultaneously, consolidated royalty growth must stay near 20% to offset persistent smartphone softness, a metric that will be scrutinized in the February and May 2027 reports. If these milestones are missed, the stock could drift toward the bear case of $210, but evidence of early shipments and stronger data-center royalties could push it back toward $330. Given the balanced risk-reward at current levels, we maintain a WAIT rating and recommend re-assessing after FQ3 FY2027 earnings or if the price approaches the attractive entry level of $220.

Thesis delta

The article confirms Arm's entry into selling its own AI host CPU but does not resolve the core debate about monetization timing, supply constraints, or margin impact. Our WAIT rating remains unchanged because the share decline is consistent with the market's demand for proof of execution rather than any deterioration in Arm's long-term architectural positioning. Until AGI CPU revenue converts on schedule and royalty growth sustains near 20%, we see no reason to alter our view that the risk-reward is balanced at current prices.